MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5001-5009

  Song, Guo qing ^a   Zhao, Yi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CCNB1; CDC25B; FOXM1; MicroRNA 211

Indexed keywords

CDC25B PHOSPHATASE; CYCLIN B1; MICRORNA; MICRORNA 211; PLASMID VECTOR; PROTEIN TYROSINE PHOSPHATASE; RENILLA LUCIFERIN 2 MONOOXYGENASE; UNCLASSIFIED DRUG; CCNB1 PROTEIN, HUMAN; CDC25B PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; MIRN211 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BASE PAIRING; BREAST CANCER CELL LINE; CANCER INHIBITION; CCNB1 GENE; CELL CYCLE REGULATION; CELL INVASION; CONTROLLED STUDY; FOXM1 GENE; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; GENE LOSS; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN B1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84938216276     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3151-6     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.
3. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010;33:637–45.
4. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (tnbc): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80–6.
5. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12 Suppl 2:S3.
6. Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.
8. Drakaki A, Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr Genomics. 2009;10:35–41.
9. Griseri P, Pages G. Regulation of the mRNA half-life in breast cancer. World J Clin Oncol. 2014;5:323–34.
10. Luo EC, Chang YC, Sher YP, Huang WY, Chuang LL, Chiu YC, et al. Microrna-769-3p down-regulates ndrg1 and enhances apoptosis in mcf-7 cells during reoxygenation. Sci Rep. 2014;4:5908.
11. Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–90.
12. Boutros R, Dozier C, Ducommun B. The when and wheres of cdc25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.
13. Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:495–507.
14. Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin a/cdk2 is blocked in g2 phase arrested cells independently of atm/atr. Oncogene. 2001;20:921–32.
15. Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25b phosphatase in mitosis triggers centrosomal microtubule nucleation in hela cells. J Cell Sci. 1996;109(Pt 5):1081–93.
16. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25b and cdc25c differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146:573–84.
17. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of cdc25b functions to coordinate mitotic events. Cell Cycle. 2006;5:2543–7.
18. van Vugt MA, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a g2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799–811.
19. Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of cdc25b in cancer cells by releasing sp1 from the promoter. Oncogene. 2013;32:5123–8.
20. Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, et al. Rsk promotes g2/m transition through activating phosphorylation of cdc25a and cdc25b. Oncogene. 2014;33:2385–94.
21. Lyons J, Bastian BC, McCormick F. Mc1r and camp signaling inhibit cdc25b activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013;110:13845–50.
22. Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. Microrna-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting cdc25b. Lab Invest. 2011;91:1472–9.
23. Rajewsky N. MicroRNA target predictions in animals. Nat Genet. 2006;38(Suppl):S8–S13.
24. Carthew RW. Gene regulation by microRNAs. Curr Opin Genet Dev. 2006;16:203–8.
25. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.
26. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136:586–91.
27. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.
28. Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of mitf-induced microrna-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.
29. Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. Microrna-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor chd5. PLoS One. 2012;7:e29750.
30. Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microrna-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.
31. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.
32. Zhang Z, Zhang G, Kong C. High expression of cdc25b and low expression of 14-3-3sigma is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 2014;35:2503–12.
33. Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of cdc25b in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13:931–5.
34. Yan X, Chua MS, He J, So SK. Small interfering rna targeting cdc25b inhibits liver tumor growth in vitro and in vivo. Mol Cancer. 2008;7:19.
35. Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. Mir-379 regulates cyclin b1 expression and is decreased in breast cancer. PLoS One. 2013;8:e68753.
36. Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. Grk2 negatively regulates igf-1r signaling pathway and cyclins’ expression in hepg2 cells. J Cell Physiol. 2013;228:1897–901.
37. Raychaudhuri P, Park HJ. Foxm1: a master regulator of tumor metastasis. Cancer Res. 2011;71:4329–33.
38. Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, et al. Foxm1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.
39. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. Foxm1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2010;122:337–46.